Clinical Trials
5 trialsNCT03737994 2026-04-23
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT06563999 2026-04-21
NUMER
Sun Yat-sen University
Phase 2 Recruiting
NCT04837716 2026-02-19
Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03608007 2020-01-09
X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement
Betta Pharmaceuticals Co., Ltd.
Phase 2 Unknown
NCT03536481 2019-07-24
Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers
Betta Pharmaceuticals Co., Ltd.
Phase 1 Completed